Glaucoma Coaching Program Improved Medication Adherence

Why It Matters

Improving adherence directly tackles the primary driver of glaucoma progression, offering a scalable behavioral solution for an aging, high‑risk population.

Key Takeaways

• SEE coaching raised adherence to 77.6% vs 58% control
• ≥80% adherence doubled (54.9% vs 23.7%)
• Distress scores fell; control unchanged
• No IOP difference despite better adherence
• Higher dropout in coaching arm raises feasibility concerns

Pulse Analysis

Glaucoma remains a leading cause of irreversible blindness, and the effectiveness of intra‑ocular pressure‑lowering drops hinges on patients taking them consistently. Studies estimate that up to 40% of patients fall below the 80% adherence threshold, undermining clinical outcomes and inflating long‑term costs for health systems. The SEE program, built on personalized education, reminder technology, and non‑physician coaching, directly addresses these behavioral gaps by integrating psychosocial support with real‑time monitoring, a model that aligns with value‑based care initiatives seeking measurable adherence improvements.

The trial’s findings demonstrate that a structured coaching intervention can lift average adherence by nearly 20 percentage points and more than double the proportion of patients reaching the clinically relevant 80% benchmark. Beyond raw numbers, participants reported lower glaucoma‑related distress, suggesting that the program’s educational and emotional components alleviate anxiety tied to disease management. While intra‑ocular pressure did not shift within six months, the adherence boost lays groundwork for longer‑term IOP control, as sustained medication use is a prerequisite for slowing optic nerve damage. These outcomes reinforce the notion that behavioral interventions can generate immediate quality‑of‑life benefits even before physiological markers respond.

Nevertheless, the higher attrition rate among coached patients and the study’s predominantly insured cohort signal implementation challenges. Scaling SEE will require streamlined workflows to minimize patient burden, possibly leveraging digital platforms for remote coaching. Future research should explore cost‑effectiveness, integration with electronic health records, and outcomes in uninsured or diverse socioeconomic groups. If these hurdles are addressed, personalized coaching could become a cornerstone of chronic eye‑disease management, delivering both clinical and economic value.